Cwm LLC bought a new stake in Neuronetics, Inc. (NASDAQ:STIM – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,931 shares of the company’s stock, valued at approximately $41,000.
Several other hedge funds and other institutional investors have also made changes to their positions in STIM. Nantahala Capital Management LLC bought a new position in shares of Neuronetics in the first quarter valued at $2,667,000. Assenagon Asset Management S.A. acquired a new stake in Neuronetics during the 3rd quarter valued at $833,000. Renaissance Technologies LLC acquired a new stake in Neuronetics during the 1st quarter valued at $564,000. Millrace Asset Group Inc. lifted its holdings in Neuronetics by 28.4% during the 2nd quarter. Millrace Asset Group Inc. now owns 629,731 shares of the company’s stock valued at $2,021,000 after purchasing an additional 139,395 shares during the last quarter. Finally, Cannell Capital LLC lifted its holdings in Neuronetics by 4.5% during the 1st quarter. Cannell Capital LLC now owns 2,750,353 shares of the company’s stock valued at $8,334,000 after purchasing an additional 118,131 shares during the last quarter. 62.90% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, Canaccord Genuity Group raised their price target on Neuronetics from $9.00 to $10.00 in a report on Wednesday, November 9th.
Insider Transactions at Neuronetics
Neuronetics Trading Up 5.2 %
Shares of Neuronetics stock opened at $6.03 on Friday. Neuronetics, Inc. has a 1 year low of $1.98 and a 1 year high of $6.95. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.02 and a quick ratio of 3.68. The company has a market capitalization of $164.14 million, a price-to-earnings ratio of -4.40 and a beta of 2.12. The business has a fifty day simple moving average of $6.10 and a two-hundred day simple moving average of $4.42.
Neuronetics (NASDAQ:STIM – Get Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. Neuronetics had a negative return on equity of 49.80% and a negative net margin of 58.85%. The company had revenue of $16.50 million during the quarter, compared to the consensus estimate of $14.79 million. Research analysts forecast that Neuronetics, Inc. will post -1.51 EPS for the current year.
Neuronetics Company Profile
Neuronetics, Inc commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients.
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.